Smith & Nephew plc (NYSE: SNN)‘s stock had its “neutral” rating reaffirmed by Goldman Sachs in a research note issued on Friday.

Several other analysts have also recently commented on the stock. Analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note to investors on Monday, February 25th. Separately, analysts at Zacks upgraded shares of Smith & Nephew plc from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, February 5th. They now have a $59.10 price target on the stock. Finally, analysts at JPMorgan Chase initiated coverage on shares of Smith & Nephew plc in a research note to investors on Friday, February 1st. They set a “neutral” rating on the stock.

One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $56.05.

Shares of Smith & Nephew plc (NYSE: SNN) traded up 1.82% during mid-day trading on Friday, hitting $56.97. Smith & Nephew plc has a 52 week low of $44.84 and a 52 week high of $58.24. The stock’s 50-day moving average is currently $55.11. The company has a market cap of $10.295 billion and a P/E ratio of 13.83.

The company also recently announced a semiannual dividend, which is scheduled for Wednesday, May 8th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.81 per share. This represents a dividend yield of 2.97%. The ex-dividend date is Wednesday, April 17th.

Smith & Nephew plc is a global medical devices business operating in the orthopedics, endoscopy and advanced wound management markets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.